US EditionPublished • loading... • Updated
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten
Summary by Laotian Times
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
Laotian Times+3 Reposted by 3 other sources
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten
– Accretive Commercialization Services Agreement covering six mature assets across critical care, cardiovascular, and metabolic disease leveraging Everest’s existing commercial organization– Exclusive Greater China license to develop and commercialize Lerodalcibep, a novel, small protein-binding, third-generation PCSK9 inhibitor that adds to the Company’s late-stage product pipeline– Together, these agreements drive financial and strategic syne…
Coverage Details
Total News Sources4
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
